DirectHit is a diagnostic test panel developed by CCC Diagnostics to predict patient response to breast cancer treatments. It analyzes multiple biomarkers from tissue samples using quantitative immunofluorescence to determine effectiveness of hormonal therapies, targeted drugs like Trastuzumab, and chemotherapy drugs. DirectHit aims to personalize treatment selection by identifying ineffective treatments upfront, improving outcomes and reducing costs compared to standard testing methods. CCC Diagnostics is currently expanding DirectHit to additional cancers and chemotherapy drugs based on promising early results.

1. DirectHit ® Test Panel for Breast Cancer www.cccdiag.com A Personalized Approach to Anticancer Therapy ®

9. DirectHit ® Methods FFPE Tissue Biomarkers 1. Slide Processing 2. Imaging 4. DRI Expression 3. Cancer Cell ID

10. DirectHit ® Prediction Accuracy Hormonal Treatment DirectHit ® is more accurate than standard methods 0 20 40 60 80 100 IHC 68%* DirectHit ® 94% Response Rate * Based on ongoing retrospective clinical trials

11. DirectHit ® Prediction Accuracy Trastuzumab Treatment DirectHit ® is more accurate than standard methods 0 20 40 60 80 100 IHC 44%* DirectHit ® 100% Response Rate * Based on ongoing retrospective clinical trials

12. DirectHit ® Prediction Accuracy DirectHit ® accurately predicts response to: Antiestrogens and Trastuzumab Response Rate Resistant Accuracy 100% Resistant Accuracy 100% Sensitive Accuracy 94%

13. DirectHit ® Prediction Accuracy DirectHit ® accurately predicts response to chemotherapy Response Rate